Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPARC001 is an abuse-deterrent formulation of the combination analgesic hydrocodone bitartrate and acetaminophen, developed by Sun Pharma Advanced Research Company (SPARC). It is designed to provide effective pain management while reducing the potential for misuse and abuse, particularly through common tampering routes such as crushing for snorting or extraction for injection. The formulation aims to maintain the therapeutic efficacy and pharmacokinetic profile of standard immediate-release hydrocodone/acetaminophen combinations (such as Norco) while incorporating physical and chemical barriers to tampering. SPARC001 has been evaluated in clinical trials focusing on relative bioavailability and abuse potential in recreational opioid users.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SPARC001.